Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Arterial Hypertension
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 10, No 1 (2006)
Review paper
Published online: 2006-01-28
View PDF (Polish) Download PDF file
Get Citation

The role of acetylsalicylic acid in arterial hypertension

Katarzyna Kostka-Jeziorny, Andrzej Tykarski
Nadciśnienie tętnicze 2006;10(1):60-68.

open access

Vol 10, No 1 (2006)
REVIEV
Published online: 2006-01-28

Abstract

We summarized recently published literature regarding the significance of role of aspirin in arterial hypertension. Acetylsalicylic acid (ASA, aspirin) has been commercially available as an analgesic and antiinflammatory agent for more then a century. In recent years the demonstrated ability of aspirin to inhibit platelet aggregation and prevent thrombotic cardiovascular events has made it the most important cardiovascular medication from both risk-benefit and cost-benefit standpoints. Although aspirin is effective in the treatment of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women, its use in primary prevention remains controversial, because the risk for gastrointestinal bleeding and hemorrhagic stroke may outweigh the benefit of preventing rare cardiovascular events.
Aspirin selectively decreases blood pressure as a function of timing of its administration in relation to the rest activity cycle of each individual subject. The low-dose ASA given before bedtime not only significantly reduced the mean BP (blood pressure) from ABPM (Ambulatory Blood Pressure Monitoring) but also the average of convensional BP measurements. Moreover, we mention about the resistance to aspirin, interaction between ASA and angiotensin-converting enzyme inhibitors and the role of aspirin in renography.

Abstract

We summarized recently published literature regarding the significance of role of aspirin in arterial hypertension. Acetylsalicylic acid (ASA, aspirin) has been commercially available as an analgesic and antiinflammatory agent for more then a century. In recent years the demonstrated ability of aspirin to inhibit platelet aggregation and prevent thrombotic cardiovascular events has made it the most important cardiovascular medication from both risk-benefit and cost-benefit standpoints. Although aspirin is effective in the treatment of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women, its use in primary prevention remains controversial, because the risk for gastrointestinal bleeding and hemorrhagic stroke may outweigh the benefit of preventing rare cardiovascular events.
Aspirin selectively decreases blood pressure as a function of timing of its administration in relation to the rest activity cycle of each individual subject. The low-dose ASA given before bedtime not only significantly reduced the mean BP (blood pressure) from ABPM (Ambulatory Blood Pressure Monitoring) but also the average of convensional BP measurements. Moreover, we mention about the resistance to aspirin, interaction between ASA and angiotensin-converting enzyme inhibitors and the role of aspirin in renography.

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

aspirin; primary prevention; arterial hypertension; aspirin resistance; aspirin renography; interaction between aspirin and angiotensin-converting enzyme inhibitors

About this article
Title

The role of acetylsalicylic acid in arterial hypertension

Journal

Arterial Hypertension

Issue

Vol 10, No 1 (2006)

Article type

Review paper

Pages

60-68

Published online

2006-01-28

Page views

1450

Article views/downloads

3310

Bibliographic record

Nadciśnienie tętnicze 2006;10(1):60-68.

Keywords

aspirin
primary prevention
arterial hypertension
aspirin resistance
aspirin renography
interaction between aspirin and angiotensin-converting enzyme inhibitors

Authors

Katarzyna Kostka-Jeziorny
Andrzej Tykarski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl